Funding
Funding not disclosed
Founders
Product
Problem
Current mRNA therapeutics face challenges related to stability, inefficient translation, and off-target effects, limiting their efficacy and potential for widespread clinical application. Precise and efficient delivery of mRNA to target cells remains a significant hurdle.
Solution
Amptiv Biosciences is developing a molecular toolkit designed to enhance the performance of mRNA therapeutics. Their technology focuses on improving mRNA stability to prolong its therapeutic effect, boosting translation efficiency to increase protein production, and enhancing targeting to ensure precise delivery to the intended cells. By addressing these key limitations, Amptiv aims to create more effective and safer mRNA-based treatments.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies developing mRNA-based vaccines and therapeutics, as well as academic researchers working on gene therapy and personalized medicine.
Features
- Proprietary mRNA stabilization sequences that extend transcript half-life and increase protein expression.
- Optimized 5' and 3' untranslated regions (UTRs) for enhanced ribosome recruitment and translational efficiency.
- Modular mRNA design platform allowing for rapid optimization of sequence elements.
- Cell-specific targeting ligands for precise delivery of mRNA to desired tissues.
- Modified nucleosides to reduce innate immune response and improve mRNA tolerability.